tirzepatide osteoporosis Tirzepatide, a dual GLP-1 and GIP receptor agonist, promotes bone loss in obese mice via gut microbial-related metabolites Tirzepatide and Bone Density |

Interestingly, the STEP-8 study 22 revealed a higher incidence of psychiatric events with liraglutide 3 mg (15.0%) compared to semaglutide 2.4 mg (5.6%) and placebo (10.6%)

Can you lose weight on semaglutide without changing your diet

If new safety evidence is released, a drug may lose its approval from the FDA and, thus, coverage from your insurance plan

Generic Semaglutide Now Available in Vancouver in 2026 and 2027 Novo Nordisks Canadian data exclusivity on semaglutide expired on January 4, 2026 [8]

I think with the increasing awareness of cardiometabolic comorbidities in certain diseases like psoriasis, psoriatic arthritis, and hidradenitis suppurativa, its just a matter of time before using weight loss medications like GLP-1 / GIP agonists will become a standard of care, he tells TDD

Stopping or changing a medication on your own can lead to unintended health issues or make your treatment less effective